Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CELC
- Price
- 9.23
- Stock movement up
- +0.58 (6.71%)
- Company name
- Celcuity LLC
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 342.71M
- Ent value
- 453.43M
- Price/Sales
- 1492.31
- Price/Book
- 2.29
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 29.52%
- 1 year return
- -52.37%
- 3 year return
- 1.80%
- 5 year return
- 13.00%
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CELC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1492.31 |
| Price to Book | 2.29 |
| EV to Sales | 1974.46 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 37.13M |
| EPS (TTM) | -2.20 |
| FCF per share (TTM) | -1.74 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 229.65K |
| Gross profit (TTM) | 141.03K |
| Operating income (TTM) | -96.57M |
| Net income (TTM) | -93.97M |
| EPS (TTM) | -2.20 |
| EPS (1y forward) | -3.11 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 61.41% |
| Operating margin (TTM) | -42049.61% |
| Profit margin (TTM) | -40921.12% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 12.60M |
| Net receivables | 0.00 |
| Total current assets | 272.44M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 273.04M |
| Accounts payable | 9.16M |
| Short/Current long term debt | 97.19M |
| Total current liabilities | 26.31M |
| Total liabilities | 123.33M |
| Shareholder's equity | 149.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -74.23M |
| Capital expenditures (TTM) | 237.43K |
| Free cash flow (TTM) | -74.47M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -62.77% |
| Return on Assets | -34.42% |
| Return on Invested Capital | -62.70% |
| Cash Return on Invested Capital | -49.69% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.64 |
| Daily high | 9.27 |
| Daily low | 8.54 |
| Daily Volume | 201K |
| All-time high | 30.93 |
| 1y analyst estimate | 28.86 |
| Beta | 0.75 |
| EPS (TTM) | -2.20 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2025 |
Downside potential
Loading...
Downside potential data
| CELC | S&P500 | |
| Current price drop from All-time high | -70.16% | -12.89% |
| Highest price drop | -85.64% | -56.47% |
| Date of highest drop | 16 Apr 2020 | 9 Mar 2009 |
| Avg drop from high | -48.76% | -11.07% |
| Avg time to new high | 83 days | 12 days |
| Max time to new high | 953 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
342.71M
Marketcap category
Small-cap
Description
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Employees
55
Website
Investor relations
-
SEC filings
CEO
Brian F. Sullivan
Country
USA
City
Minneapolis
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page